Sanofi India has named Rahul Bhatnagar as Chairman of the Board, effective April 30, 2026, signaling a continued emphasis on independent governance at the top of the company. As an Independent Director, Bhatnagar takes the helm at a moment when the board is also formalizing a broader governance refresh that underscores the importance of oversight and strategy in driving the company’s long-term objectives.
In the same Board meeting, the company noted the completion of the tenure of two Independent Directors, Aditya Narayan and Usha Thorat, whose terms will end with the close of business hours on April 29, 2026. The Board has placed on record its appreciation for their contributions and the guidance they provided during their tenure, marking a transitional moment for Sanofi India’s governance framework.
A reconstitution of key Board committees, effective April 30, 2026, accompanies the leadership change. Rajani Kesari steps in as Chairperson of the Audit Committee, with Siraj Chaudhry serving as a member and Vaibhav Karandikar as a member. For the Nomination and Remuneration Committee, Siraj Chaudhry is the Chairperson, joined by Rajani Kesari and Eric Mansion. The Stakeholders Relationship Committee will be chaired by Siraj Chaudhry, with Deepak Arora and Rachid Ayari as members. The Risk Management Committee will see Rajani Kesari as Chairperson, with Siraj Chaudhry, Rachid Ayari, Mahadev Gawade, and Deepak Arora as members, while the Corporate Social Responsibility Committee will be chaired by Siraj Chaudhry with Rajani Kesari and Deepak Arora as members. These changes reflect a concerted push to align governance with Sanofi India’s strategic priorities and operational rigor.
Beyond the governance updates, Sanofi India continues to highlight its insulin portfolio and broader strategic partnerships across cardiovascular, diabetes care, and CNS segments, underscoring a focus on sustained growth through continued execution, efficiency, and market expansion. As the board reshapes its leadership and committee structure, the company appears poised to pursue its ambitions while maintaining a strong emphasis on independence, accountability, and governance excellence.